Haemonetics Corporation Financial Statements (HAE)
|
|
|
|
Report date
|
|
|
22.05.2023 |
31.03.2024 |
20.05.2024 |
21.05.2025 |
07.05.2026 |
|
07.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
1 169 |
|
1 309 |
1 361 |
1 334 |
|
1 334 |
|
Operating Income, bln rub |
|
|
156.0 |
|
164.9 |
221.8 |
241.4 |
|
241.4 |
|
EBITDA, bln rub |
? |
|
252.0 |
|
295.5 |
356.0 |
397.1 |
|
252.9 |
|
Net profit, bln rub |
? |
|
115.4 |
|
117.6 |
167.7 |
97.3 |
|
97.3 |
|
|
OCF, bln rub |
? |
|
273.1 |
|
181.8 |
181.7 |
293.2 |
|
293.2 |
|
CAPEX, bln rub |
? |
|
110.2 |
|
66.3 |
39.3 |
32.8 |
|
32.8 |
|
FCF, bln rub |
? |
|
162.9 |
|
115.5 |
142.4 |
260.4 |
|
260.4 |
|
Dividend payout, bln rub
|
|
|
0.000 |
|
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
|
|
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
|
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
466.8 |
|
547.0 |
556.7 |
502.2 |
|
502.2 |
|
Cost of production, bln rub |
|
|
545.8 |
|
597.1 |
582.3 |
590.4 |
|
590.4 |
|
R&D, bln rub |
|
|
58.6 |
|
63.0 |
69.4 |
59.8 |
|
59.8 |
|
Interest expenses, bln rub |
|
|
14.6 |
|
13.0 |
9.75 |
28.7 |
|
24.8 |
|
|
Assets, bln rub |
|
|
1 935 |
2 196 |
2 196 |
2 451 |
2 396 |
|
2 396 |
|
Net Assets, bln rub |
? |
|
818.0 |
960.0 |
960.0 |
820.8 |
893.8 |
|
796.3 |
|
Debt, bln rub |
|
|
765.9 |
807.8 |
807.8 |
1 225 |
1 225 |
|
1 225 |
|
Cash, bln rub |
|
|
284.5 |
178.8 |
178.8 |
306.8 |
245.4 |
|
245.4 |
|
Net debt, bln rub |
|
|
481.4 |
629.0 |
629.0 |
918.0 |
979.1 |
|
979.1 |
|
|
Ordinary share price, rub |
|
|
82.8 |
85.4 |
85.4 |
|
|
|
85.4 |
|
Number of ordinary shares, mln |
|
|
50.8 |
|
50.7 |
50.3 |
47.2 |
|
46.2 |
|
|
Market cap, bln rub |
|
|
4 202 |
0 |
4 328 |
0 |
0 |
|
3 946 |
|
EV, bln rub |
? |
|
4 684 |
629 |
4 957 |
918 |
979 |
|
4 925 |
|
Book value, bln rub |
|
|
76 |
-11 |
-11 |
-239 |
-210 |
|
-308 |
|
|
EPS, rub |
? |
|
2.27 |
|
2.32 |
3.33 |
2.06 |
|
2.11 |
|
FCF/share, rub |
|
|
3.21 |
|
2.28 |
2.83 |
5.52 |
|
5.63 |
|
BV/share, rub |
|
|
1.50 |
|
-0.22 |
-4.75 |
-4.46 |
|
-6.66 |
|
|
EBITDA margin, % |
? |
|
21.6% |
|
22.6% |
26.2% |
29.8% |
|
19.0% |
|
Net margin, % |
? |
|
9.87% |
|
8.98% |
12.3% |
7.29% |
|
7.29% |
|
FCF yield, % |
? |
|
3.88% |
0.00% |
2.67% |
|
|
|
6.60% |
|
ROE, % |
? |
|
14.1% |
0.00% |
12.2% |
20.4% |
10.9% |
|
12.2% |
|
ROA, % |
? |
|
5.96% |
0.00% |
5.35% |
6.84% |
4.06% |
|
4.06% |
|
|
P/E |
? |
|
36.4 |
|
36.8 |
0.00 |
0.00 |
|
40.5 |
|
P/FCF |
|
|
25.8 |
|
37.5 |
0.00 |
0.00 |
|
15.1 |
|
P/S |
? |
|
3.60 |
|
3.31 |
0.00 |
0.00 |
|
2.96 |
|
P/BV |
? |
|
55.3 |
0.00 |
-385.0 |
0.00 |
0.00 |
|
-12.8 |
|
EV/EBITDA |
? |
|
18.6 |
|
16.8 |
2.58 |
2.47 |
|
19.5 |
|
Debt/EBITDA |
|
|
1.91 |
|
2.13 |
2.58 |
2.47 |
|
3.87 |
|
|
R&D/CAPEX, % |
|
|
53.2% |
|
95.1% |
176.7% |
182.3% |
|
182.3% |
|
|
CAPEX/Revenue, % |
|
|
9.43% |
|
5.06% |
2.89% |
2.46% |
|
2.46% |
|
| Haemonetics Corporation shareholders |
